This month, Xeomin® (incobotulinumtoxinA) was approved by the FDA for treatment of frown lines and wrinkles in the glabellar region. Slated to be released in the Spring of 2012, Xeomin® follows Botox and Dysport to treat dynamic wrinkles (or wrinkles caused by muscle movement), which is popular in the glabella and Crow’s feet regions.
It’s too early to tell what type of results to expect and whether patients will like Xeomin® more than Botox or Dysport. We will have to wait to see what the results will be and how it will compare to its predecessors to see if it is worth having in the office.
Back to blog